Clinical ophthalmology (Auckland, N.Z.)最新文献

{"title":"Real-World Efficacy of Intravitreal Faricimab for Macular Edema Secondary to Retinal Vein Occlusion: Short-Term Outcomes and Optical Coherence Tomography Biomarker Analysis.","authors":"Soichiro Inokuchi, Yuki Mizuki, Akihiro Kamata, Junji Onishi, Takahiko Hayashi, Nobuhisa Mizuki","doi":"10.2147/OPTH.S549896","DOIUrl":"https://doi.org/10.2147/OPTH.S549896","url":null,"abstract":"<p><strong>Background: </strong>Retinal vein occlusion (RVO) is the second most common retinal vascular disease and a major cause of visual impairment due to macular edema (ME). Faricimab, a novel bispecific antibody targeting both VEGF-A and angiopoietin-2, has shown promise in clinical trials; however, real-world data on its efficacy and safety for ME secondary to RVO (RVO-ME) remain limited.</p><p><strong>Objective: </strong>To evaluate the short-term efficacy and safety of intravitreal faricimab for RVO-ME in a real-world Japanese clinical setting, and to explore associations between baseline optical coherence tomography (OCT) biomarkers and treatment outcomes.</p><p><strong>Methods: </strong>This retrospective observational study was conducted at the International Goodwill Hospital, Yokohama, Japan, and included 23 eyes with RVO-ME treated with intravitreal faricimab. Changes in best-corrected visual acuity (BCVA, logMAR) and central subfield thickness (CST) over 3 months were assessed. Baseline OCT biomarkers were analyzed for associations with visual and anatomical responses. Subgroup analyses compared treatment-naïve and previously treated eyes.</p><p><strong>Results: </strong>The median number of injections was 1, and 52.2% of eyes achieved complete resolution of macular fluid. Median BCVA improved significantly from 0.40 to 0.22 logMAR (<i>p</i> = 0.0025), and median CST decreased from 352 µm to 194 µm (<i>p</i> < 0.001). Greater CST reduction was observed in treatment-naïve eyes (<i>p</i> = 0.048) and in eyes with chronic cyst (<i>p</i> = 0.015). No OCT biomarker was significantly associated with BCVA improvement. No ocular or systemic adverse events were observed.</p><p><strong>Conclusion: </strong>Intravitreal faricimab was effective and well-tolerated for RVO-ME in this real-world study. Even a single injection frequently led to anatomical and functional improvement. These results support the clinical utility of faricimab and suggest a potential role for OCT biomarkers in predicting treatment response.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3669-3679"},"PeriodicalIF":0.0,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506786/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Filling in the Blind Spot: Integrating Charles Bonnet Syndrome Screening in Ophthalmology.","authors":"Philip John Borsellino, Savannah Schauer, Axel Rivas, Karl Aharonian, Thomas A Vida","doi":"10.2147/OPTH.S547122","DOIUrl":"https://doi.org/10.2147/OPTH.S547122","url":null,"abstract":"<p><strong>Purpose: </strong>Charles Bonnet Syndrome (CBS) is an underdiagnosed condition affecting patients with significant vision loss who experience complex visual hallucinations while maintaining cognitive insight. This scoping review aims to synthesize existing literature on CBS prevalence, risk factors, and screening practices, and to propose a standardized, clinically implementable screening workflow for ophthalmologists.</p><p><strong>Patients and methods: </strong>We conducted a structured literature search across four databases (PubMed, Embase, Web of Science, Scopus) using keywords related to CBS, visual impairment, screening, and diagnosis. Inclusion criteria encompassed peer-reviewed studies involving patients with vision loss that reported the use of screening tools, diagnostic criteria, or clinical assessments of CBS. Excluded were case reports with fewer than five patients, articles lacking full text or peer review, and those focused primarily on psychiatric or neurologic hallucinations. We identified 1,582 articles, with 89 studies meeting the final inclusion criteria.</p><p><strong>Results: </strong>CBS prevalence ranged from 2% to 30%, depending on the underlying ocular condition and screening method used. Age-related macular degeneration showed the highest association. Few studies utilized validated screening tools though the QR-SCB and NEVHI instruments demonstrated clinical utility. Barriers to diagnosis included patient reluctance to report symptoms and clinician unfamiliarity. We developed a pragmatic clinical model incorporating risk stratification, direct questioning, validated tools, and functional assessment to improve detection in ophthalmology clinics.</p><p><strong>Conclusion: </strong>CBS remains underdiagnosed despite its significant psychosocial burden. A structured screening approach may increase diagnostic accuracy and support timely intervention. The proposed model offers ophthalmologists a practical pathway to integrate CBS assessment into routine care.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3619-3657"},"PeriodicalIF":0.0,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502960/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Hemorrhagic Complications and Secondary Surgery in Patients on Warfarin vs DOACs Undergoing Glaucoma Surgery.","authors":"Hasan Ehsan, Zainub Abdullah, Misha F Syed","doi":"10.2147/OPTH.S542378","DOIUrl":"https://doi.org/10.2147/OPTH.S542378","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the risk of postoperative ocular hemorrhagic complications and reoperation in glaucoma surgery patients taking warfarin versus direct oral anticoagulants (DOACs).</p><p><strong>Patients and methods: </strong>This retrospective cohort study used the TriNetX global federated health research network. We identified 15,336 glaucoma surgery patients on warfarin and 22,358 on DOACs between January 1, 2000 and January 1, 2025. After 1:1 propensity score matching for age, gender, race, Type 2 Diabetes, hypertension, hyperlipidemia, and nicotine dependence, 15,019 patients remained in each cohort. We analyzed postoperative hemorrhagic complications within 1 year, including vitreous, conjunctival, retinal, and choroidal hemorrhages; hyphema; mitomycin injection; and periocular hemorrhage. Risk ratios (RRs) and 95% confidence intervals (CIs) were calculated, with significance set at p < 0.05. A secondary analysis assessed reoperation risk among those who experienced hemorrhagic complications. Patients on anticoagulants were compared to glaucoma patients with hemorrhagic complications who were not on anticoagulants. Reoperations included repeat trabeculectomy and aqueous shunt revision/insertion.</p><p><strong>Results: </strong>Warfarin was associated with significantly higher risk of vitreous hemorrhage (RR 1.949, CI 1.563-2.321, p < 0.0001), conjunctival hemorrhage (RR 1.329, CI 1.007-1.710, p = 0.0459), retinal hemorrhage (RR 1.512, CI 1.145-1.997, p = 0.0033), and hyphema (RR 1.740, CI 1.240-2.462, p = 0.0015). No increased risk was found for choroidal hemorrhage or postoperative mitomycin C injection. Hemorrhagic complications did not increase reoperation risk in patients on anticoagulants compared to controls.</p><p><strong>Conclusion: </strong>Warfarin use is linked to higher ocular hemorrhagic complication rates post-glaucoma surgery compared to DOACs. Anticoagulants use did not increase the risk of reoperation.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3659-3667"},"PeriodicalIF":0.0,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12502955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145254095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conscious Monitored Anesthesia Care versus General Anesthesia for Vitreoretinal Surgeries.","authors":"Ehsan Namvar, Alireza Attar, Mehrdad Salari, Mohammad Alamdari, Maryam Hadipour","doi":"10.2147/OPTH.S546027","DOIUrl":"10.2147/OPTH.S546027","url":null,"abstract":"<p><strong>Purpose: </strong>This study compares monitored anesthesia care (MAC) with general anesthesia (GA) for vitreoretinal surgery, aiming to assess safety, efficacy, and patient outcomes.</p><p><strong>Patients and methods: </strong>This was a prospective non-randomized clinical trial. This trial was conducted during vitreoretinal surgery. Forty Patients were included in this study and divided into MAC and GA groups. The patients were divided in to two groups. In one group, patients who were operated under general anesthesia and in the other group those who were operated with conscious sedation were included. Anesthesia quality, surgical outcomes, anesthesia time, surgery time and recovery time were compared between two groups using standardized criteria and statistical analysis.</p><p><strong>Results: </strong>MAC provided comparable analgesia, immobilization, and hemodynamic stability to GA, with no reported complications. All patients in both groups had successful surgery. Anesthesiologist favored MAC for its hemodynamic control, while surgeons showed no preference. MAC exhibited shorter anesthesia time than GA with lower anesthetics. These findings support the use of MAC in vitreoretinal surgery, especially for patients at risk of complications from GA.</p><p><strong>Conclusion: </strong>Moderate sedation with MAC offers a safe and effective alternative to GA for vitreoretinal surgery, with similar outcomes, reduced anesthesia time, and lower drug doses. Further research with larger cohorts is warranted to validate these results and refine anesthesia protocols.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3595-3601"},"PeriodicalIF":0.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499363/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficiency Comparison Between Two Different Lasers and Cataract Surgery Workflows: A Prospective and Retrospective Analysis.","authors":"Jack M Chapman","doi":"10.2147/OPTH.S548211","DOIUrl":"10.2147/OPTH.S548211","url":null,"abstract":"<p><strong>Purpose: </strong>To compare time efficiencies between a traditional femtosecond laser platform and workflow and a single-room model with a robotic laser in patients undergoing cataract surgery.</p><p><strong>Patients and methods: </strong>Single site, prospective, non-masked study of 23 patients (n = 23 eyes) who underwent the femtosecond laser portion of their cataract surgery with the LenSx Femtosecond Laser System (Alcon, Ft. Worth, Texas) in one room and were subsequently moved to a second room for the remainder of their surgery compared to 23 patients who underwent surgery with a dual-modality, robotic laser (ALLY, Lensar, Orlando, FL) and remained in the same room for the rest of the surgery. Time parameters evaluated were laser set up, docking, suction, total laser time, docking attempts, surgeon total case time, patient total case time, transition to phacoemulsification start time, and transition preparation and draping. Third party observers tracked all time and motion parameters by using a stopwatch and documented activities with a time stamp.</p><p><strong>Results: </strong>There were statistical differences in numerous parameters (all outcomes were measured in minutes): mean suction time [ALLY, 1:16 vs LenSx, 2:26, (<i>P</i> < 0.001)], laser completion to phacoemulsification initiation [ALLY, 0:57 vs LenSx, 4:39, (P < 0.001)], laser set up start to docking start [ALLY, 10:05 vs LenSx, 19:31, (<i>P</i> = 0.034)], total laser time for the surgeon [ALLY, 3:17 vs LenSx, 4:53; (<i>P</i> = <0.001)]; total case time for the surgeon [ALLY, 14:27 vs LenSx,19:40; (<i>P</i> < 0.001)], and total patient time spent in the OR [ALLY, 25:25 vs LenSx 33:22; (<i>P</i> = 0.021)]. There were no statistically significant differences in total phaco procedure time.</p><p><strong>Conclusion: </strong>Using a robotic laser for cataract surgery can save about 5 minutes of surgeon time per case and 8 minutes of patient's time in the OR when compared to a traditional femtosecond laser platform set up.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3603-3608"},"PeriodicalIF":0.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499575/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Four Lens Power Formulas for Sutureless Scleral-Fixated Carlevale Lens.","authors":"Agnieszka Dyrda, Liliana Araujo-Diaz, Amanda Rey, Maria S Pighin, Marta Pazos, Ignasi Jürgens","doi":"10.2147/OPTH.S535925","DOIUrl":"10.2147/OPTH.S535925","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the predictability of intraocular lens (IOL) power calculation formulas for sutureless scleral fixation (SSF) of the Carlevale IOL.</p><p><strong>Methods: </strong>A prospective, single-center, interventional case series was conducted to compare predicted refractive outcomes using the SRK/T, Barrett II, Hoffer Q, and Holladay 1 formulas in patients undergoing SSF of the Carlevale IOL. The main outcomes included mean prediction error (PE), median absolute error (MedAE), mean absolute error (MAE), and the percentage of eyes with a PE within ±0.50 and ±1.0 diopters (D).</p><p><strong>Results: </strong>Sixty-nine eyes of 69 patients were included. Only the Barrett II formula resulted in a systematic myopic error (p=0.014). The PE of SRKT, HofferQ, and Holladay 1 was closer to 0, indicating that the post-operative refractive outcome was nearer to the predicted value than that of Barrett II (p=0.002, p<0.001, p=0.003, respectively). MedAE and MAE ranged from 0.41 to 0.53 D and 0.6 to 0.67 D, respectively, without significant differences between the formulas. The percentages of eyes with PE within ±0.50 and ±1.00 D varied from 47.8 to 56.5% and 79.7 to 87%, respectively, showing no significant differences across the assessed formulas.</p><p><strong>Conclusion: </strong>The SRK/T, Hoffer Q, and Holladay 1 formulas provide favorable refractive outcomes for the SSF of Carlevale IOL. The Barrett II formula is less accurate and is not recommended due to its systematic myopic refractive error.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3609-3617"},"PeriodicalIF":0.0,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12499570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145245942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Profile and Outcomes of Patients with Toxoplasmic Retinochoroiditis: A Tertiary Care Center Experience.","authors":"Hanan A Alshalan, Nora A Alyousif, Raneem Jannadi, Hassan Al-Dhibi","doi":"10.2147/OPTH.S552531","DOIUrl":"10.2147/OPTH.S552531","url":null,"abstract":"<p><strong>Background: </strong>This study aims to characterize the demographic profile, clinical features, and treatment outcomes of patients diagnosed with toxoplasmic retinochoroiditis (TRC) at a tertiary care center in Riyadh, Saudi Arabia.</p><p><strong>Methods: </strong>A retrospective chart review was conducted on patients presenting to the uveitis service at King Khaled Eye Specialist Hospital between 2018 and 2024 with clinical signs consistent with TRC. Demographic data, clinical findings, multimodal imaging results, treatment regimens, and disease complications were collected and analyzed.</p><p><strong>Results: </strong>Thirty-three eyes of 33 patients met inclusion criteria, with a mean age of 36.5 ± 11.8 years. Recurrent disease was observed in 78.8%, while 21.2% presented with primary TRC. Lesions predominantly involved the macula (41.9%), followed by major vascular arcades (25.8%) and peripapillary regions (22.6%), with fewer cases in mid-peripheral or peripheral retina (9.7%). Optic neuritis and neuroretinitis were observed in a small subset. Ipsilateral inactive scars were common (69.7%), and contralateral scars were present in 42.4%. Complications during follow-up included optic atrophy, macular scarring, retinal tears, epiretinal membrane formation, and choroidal and retinal neovascularization.</p><p><strong>Conclusion: </strong>Toxoplasmic retinochoroiditis has diverse clinical presentations with a substantial risk of vision-threatening complications. Therefore, early recognition, especially in patients without prior chorioretinal scars, is critical for timely intervention. This study fills a crucial knowledge gap in the regional epidemiology and management of TRC, highlighting the need for larger prospective studies to refine diagnostic criteria, optimize treatment strategies, and improve long-term visual outcomes.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3583-3593"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12497377/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Incidence of Post-Operative Fibrinoid Syndrome in Diabetic Eyes Receiving a Dexamethasone Implant During Pars Plana Vitrectomy Surgery.","authors":"Reem ElSheikh, Sairi Zhang, Mohammad Z Siddiqui, Muhammad Z Chauhan, Ahmed B Sallam, Sami H Uwaydat","doi":"10.2147/OPTH.S536499","DOIUrl":"10.2147/OPTH.S536499","url":null,"abstract":"<p><strong>Introduction: </strong>The dexamethasone implant (DEX) and pars plana vitrectomy (PPV) are both used to treat diabetic retinopathy. A rare complication of vitrectomy is post-operative fibrinoid syndrome (POFS). We report the incidence of POFS when PPV is combined with DEX injection in diabetic eyes.</p><p><strong>Methods: </strong>One hundred and five eyes of patients with diabetic retinopathy undergoing concurrent PPV and DEX were retrospectively analyzed.</p><p><strong>Results: </strong>Mean BCVA improved from 1.06 logMAR to 0.78 (p=0.05) at final follow-up. Mean CST was found to have a statistically insignificant decrease from 360 ± 154 µm to 314 ± 99 µm at final visit (p=0.13). Four eyes (3.8%) developed POFS. No major surgical complications were encountered.</p><p><strong>Conclusion: </strong>Combining PPV with DEX is safe and effective in patients with diabetic retinopathy. Our results showed an improvement in mean BCVA and a decrease in CST. The incidence of POFS was 3.8%, which is not significantly different from previously published data in 1982.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3567-3572"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Post-Operative Outcomes between IOP-20 and IOP-50 in Phacoemulsification with Active Fluidics System: Randomized Single Blinded Trial.","authors":"Chandrashekhar M Wavikar, Mamta N Tanna, Gargi C Wavikar, Chandrashekhar B Kale, Maninder Singh Setia","doi":"10.2147/OPTH.S542284","DOIUrl":"10.2147/OPTH.S542284","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the central corneal thickness, mitigation events, post-operative vision, and complications in patients who underwent cataract surgery using the CENTURION ^® Vision System with the ACTIVE SENTRY ^® (Alcon Industries, Inc.) system and were assigned to one of two groups: intraocular pressure (IOP) group 20 or 50.</p><p><strong>Setting: </strong>Wavikar Eye Institute, Thane, India.</p><p><strong>Design: </strong>A prospective comparative two arm, randomized, single blinded, interventional study.</p><p><strong>Methods: </strong>A total of 107 eyes were randomized to either the IOP-20 (n=55) or IOP-50 (n=52) group. All patients underwent phacoemulsification with an active fluidics system performed by a single surgeon; intraocular pressure (IOP) was set at either 20 or 50 mmHg.</p><p><strong>Results: </strong>The mean [SD] baseline CCT in the IOP-20 group was 511.9 [35.7] μm and it was 521.1 [34.8] μm in the IOP 50 group (p=0.18). It had changed to 530.6 [39.8] μm in the IOP-20 group and 539.5 [39.2] μm in the IOP 50 (p=0.24). The mean [SD] ECD at the end of day 90 was 2423.0 [204.6] cells/mm² in the IOP-20 group and 2476.1 [236.0] cells/mm² in the IOP-50 group (p=0.22). Approximately 22% of the eyes in the IOP-20 group and 77% of the eyes in the IOP-50 group required active surge mitigation; this difference was statistically significant (p<0.001).</p><p><strong>Conclusion: </strong>We found that the phacoemulsification with an active fluidics system handpiece at 20 mmHg provided a safe and stable environment for cataract surgery.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3573-3582"},"PeriodicalIF":0.0,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12495955/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145234533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Intravitreal Brolucizumab in Chronic Central Serous Chorioretinopathy: A Retrospective Cohort Study.","authors":"Somnath Chakraborty, Jay U Sheth, Santanu Ganguly, Rahul Reddy","doi":"10.2147/OPTH.S550375","DOIUrl":"10.2147/OPTH.S550375","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the anatomical and functional outcomes and treatment burden of intravitreal brolucizumab in chronic central serous chorioretinopathy (cCSCR) over 12 months in a real-world setting.</p><p><strong>Patients and methods: </strong>In this retrospective, single-center cohort, 29 eyes with cCSCR received pro re nata intravitreal brolucizumab. Baseline OCT angiography excluded macular neovascularization. Patients were seen monthly for three months, then as needed through month 12. At each visit, best-corrected visual acuity (BCVA), central retinal thickness (CRT), and presence of SRF, intraretinal fluid (IRF), and pigment epithelium detachment (PED; including PED height) were recorded. Total injections per eye were tallied.</p><p><strong>Results: </strong>Twenty-nine eyes (mean age 55.2±11.0 years; 72% male) with cCSCR received 1.72 ± 0.62 intravitreal brolucizumab injections over 12 months. Vision improved from BCVA 0.59 ± 0.23 logMAR at baseline to 0.46 ± 0.22 at one month (<i>P</i>=0.002), 0.40 ± 0.20 at three months (<i>P</i><0.001), and 0.39 ± 0.20 at month 12 (<i>P</i><0.001). Mean CRT reduced from 340 ± 140 µm to 260 ± 110 µm at one month and stabilized at 230 ± 98 µm by month 12 (<i>P</i><0.001). Mean PED height decreased from 48 ± 55 µm at baseline to 13 ± 17 µm at month 12 (<i>P</i><0.001). Fluid resolution was rapid and sustained; SRF cleared in 63% at one month (<i>P</i><0.001) and 88.9% at 12 months (<i>P</i><0.001), IRF in 85.7% by month 3 (<i>P</i>=0.016) and 71.4% by month 12 (<i>P</i>=0.063), and PEDs in 43.8% at one month (<i>P</i>=0.021) rising to 68.8% at month 12 (<i>P</i>=0.001). No ocular or systemic adverse events occurred.</p><p><strong>Conclusion: </strong>Intravitreal brolucizumab provided significant and sustained visual and anatomical improvements in cCSCR with a low injection burden over 12 months. Given the off‑label use and absence of a control group, findings should be interpreted cautiously and confirmed in prospective controlled studies.</p>","PeriodicalId":93945,"journal":{"name":"Clinical ophthalmology (Auckland, N.Z.)","volume":"19 ","pages":"3557-3565"},"PeriodicalIF":0.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484111/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}